Evidence map›Paper›PMID 31211907›Full record

ArticleEuropean journal of haematology2019

The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphoma.

Colm Keane, Joshua Tobin, Jay Gunawardana, Santiyagu Francis, Grace Gifford, Sara Gabrielli, Anthony Gill, William Stevenson, Dipti Talaulikar, Clare Gould and 4 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of haematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 58 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Programmed cell death-ligand 1 (PD-L1)Clinical and experimental medicine · 2022
    Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Colm KeaneMater Research, Translational Research Institute, University of Queensland, Brisbane, Queensland, Australia.ORCID https://orcid.org/0000-0002-9009-9934
Joshua TobinMater Research, Translational Research Institute, University of Queensland, Brisbane, Queensland, Australia.
Jay GunawardanaMater Research, Translational Research Institute, University of Queensland, Brisbane, Queensland, Australia.
Santiyagu FrancisMater Research, Translational Research Institute, University of Queensland, Brisbane, Queensland, Australia.
Grace GiffordKolling Institute of Medical Research, University of Sydney, Sydney, New South Wales, Australia.
Sara GabrielliKolling Institute of Medical Research, University of Sydney, Sydney, New South Wales, Australia.
Anthony GillKolling Institute of Medical Research, University of Sydney, Sydney, New South Wales, Australia.
William StevensonKolling Institute of Medical Research, University of Sydney, Sydney, New South Wales, Australia.
Dipti TalaulikarCanberra Hospital, Canberra, Australian Capital Territory, Australia.
Clare GouldMater Research, Translational Research Institute, University of Queensland, Brisbane, Queensland, Australia.
Sanjiv JainCanberra Hospital, Canberra, Australian Capital Territory, Australia.
Simone BirchPrincess Alexandra Hospital, Brisbane, Queensland, Australia.
Mark HertzbergPrince of Wales Hospital, Sydney, New South Wales, Australia.
Maher K GandhiMater Research, Translational Research Institute, University of Queensland, Brisbane, Queensland, Australia.
Translational Research Institute · AUThe University of Sydney · AUAustralian National University · AUPrince of Wales Hospital · AUQueensland Health · AU

Funding

Cancer AustraliaCancer Cure AustraliaEducation and Research CommitteeHaematology Society of Australia and New Zealand New Investigator AwardKasey-Anne Lymphoma Giving FundLeukaemia Foundation Bridgestone AwardLord Mayor's Charitable FoundationNHMRC Early Career FellowshipPathology Queensland Study, Education and Research Committee
6 · The paper itself

Abstract

objectiveEpstein-Barr virus-positive diffuse large B-cell lymphoma (EBV

methodsWe used the NanoString™ platform in a population-based cohort of 433 patients to establish if the technology could detect EBV in the tumour biopsies and to investigate the influence that EBV has on the complex tumour microenvironment of DLBCL.

resultsIncidence of EBV

conclusionIn EBV

Indexed as

Immune ToleranceAdultAgedBiomarkers, TumorCell Transformation, ViralEpstein-Barr Virus InfectionsGene ExpressionHerpesvirus 4, HumanHumansKaplan-Meier EstimateLymphoma, Large B-Cell, DiffuseMiddle AgedNeoplasm StagingPrognosisTumor MicroenvironmentBiomarkers, Tumordiffuse large B-cell lymphomaEpstein-Barr virusimmune checkpointstumour-associated macrophagestumour microenvironment

Identifiers

PMID31211907
PMCPMC6899834
OpenAlexW2953208154

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.